UnityPoint Health – Des Moines Institutional Review Board

To move through this document, please keep document "locked" and use "Tab" key. For pediatric oncology studies, please return the signed form to Katy Juhl at Katy.Juhl@unitypoint.org For all other studies, please return the signed from to Joan Pruisner at Joan.Pruisner@unitypoint.org.

Utilization of Pharmacy for Clinical Investigations

In addition to requiring Institutional Review Board (IRB) approval for a clinical investigation to be conducted at UnityPoint Health—Des Moines, utilization of pharmacy services must be approved in advance by the service line director.

Note: In the event the protocol has changes that significantly affect the conduct of the study, the department managers may re-evaluate the utilization of their department's services for this protocol.

Protocol Title:				
Principal Investigator:				
Telephone:				
Study to be conducted at: IMMC ILH Blank Other site (describe)				
Date of planned study initiation:				
Expected enrollment for your site:				
Expected duration of study:				
Outpatient or Inpatient study: Inpatient Outpatient				
Time of day patients are expected to be enrolled (eg. 24 hours a day, day-shift only)				

April 2022 1

Pharmacy Department

Contact Name:

If you are unable to answer any of the following questions, please provide a contact name/number for the study sponsor or contract research organization so the pharmacy department can contact them for more information.

Co	ompan	y:				
Τe	elephor	ne Number:				
E-	mail:					
	1.	Will pharmacy randomize?		Yes		No
	2.	What medications need dispensed?				
	3.	What dosage form are the medications (IV, PO, SC, etc)?				
	4.	Is there a time limit on drug preparation?		Yes		No
	 If there is a time limit on drug preparation, what is the time lim 					-
6. How often is drug dispensed for each participant?						
	7. What is the length of treatment for each participant?8. What time of the day will most participants be enrolled?					
	9.	If enrollment begins as inpatient, is there a possibility of transferring to home health?		Yes		No
	10.	Will pharmacy participate in monitoring visits?		Yes		No

- □ The utilization of pharmacy services for this protocol is approved (see below for any restrictions or concerns)
- □ The utilization of pharmacy services for this protocol is not feasible (see below for explanation)

April 2022 2

Restrictions or concerns:						
Executive Director of Pharmacy	Date					

April 2022 3